Emmanuel Normant

Emmanuel Normant has extensive experience in the field of pharmaceuticals and translational sciences. Emmanuel has held various roles in different companies, starting with TG Therapeutics, Inc. in 2017 as the Vice President of Preclinical & Translational Sciences. Prior to that, they worked at Surface Oncology Inc. from 2015 to 2017 as the Director of I/O Pharmacology, where they focused on in vivo pharmacology for immuno-oncology projects using biologics, as well as translational science and external collaborations. From 2011 to 2015, Emmanuel was the Director of Epigenetic Pharmacology at Constellation Pharmaceuticals, where they specialized in epigenetic mechanisms. Before that, they worked at Infinity Pharmaceuticals from 2002 to 2011 as the Associate Director of Cancer Biology. Emmanuel first entered the industry as a Senior Scientist at Pfizer in 1998 and started their career as a Postdoc at the NIH from 1995 to 1998. Overall, Emmanuel Normant has a strong background in preclinical and translational sciences, with a focus on oncology and pharmacology.

Emmanuel Normant completed their education in a chronological order, starting with their studies at Université Paris-Saclay from 1983 to 1989. During this period, they earned a degree in pharmacy, referred to as a PharmD. Following this, they enrolled at Sorbonne Université from 1990 to 1995, where they pursued a Ph.D. in Cellular and Molecular Biology.